>Bruce Leicher, general counsel of Momenta Pharmaceuticals (MNTA.O) which makes both original and follow-on biologics, said his company supported a shorter exclusivity period.
He argued that a shorter exclusivity period would push biotechnology companies to move onto developing the next new drug, while the 12-year period would actually slow innovation<
few attorneys have ethics, they will take whichever side of an argument that they are being paid by.
What biotech company would pay hundreds of millions of dollars to pay for trials just to get five years exclusivity. If the innovator only gets five years exclusivity innovation would die.
Market Data 
Markets 
AI
